The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis.

Myeloma Patients Europe (MPE) will be attending EHA to keep the patient community informed about key developments in treatment and care. Throughout the event, we will share real-time updates via our social media channels (LinkedIn, Facebook, Instagram, X and YouTube), including expert video interviews and key highlights from the scientific sessions.

MPE will also participate in various parts of the congress programme, including the satellite symposia, the EHA-Patient Joint Symposium and poster sessions. Make sure you are following us to receive real-time updates during the events.

Key research in myeloma and AL amyloidosis at EHA 2026

The EHA 2026 scientific programme includes many abstracts on myeloma and AL amyloidosis, covering both established and new treatment approaches. While this article won’t summarise all relevant research, these are the presentations which we believe will be of greatest interest to patients and the wider myeloma and AL amyloidosis community:

Many presentations will present positive results of bispecific antibodies in myeloma, including: 

• Teclistamab: results from the phase III MajesTEC-9 clinical trial show the benefits of teclistamab monotherapy compared with standard of care combinations in patients with relapsed or refractory myeloma. 
• Teclistamab and daratumumab: analyses from the phase III MajesTEC-3 clinical trial demonstrate the efficacy of teclistamab plus daratumumab across high-risk subgroups of patients with relapsed or refractory myeloma. 
• Talquetamab: results from the phase III MONUMENTAL-3 clinical trial show the benefits of talquetamab plus daratumumab with or without pomalidomide compared to a combination of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma. 
  
  
• Infection prevention with BCMA bispecific antibodies: results from a retrospective, real-world study show that primary prophylaxis (treatment before any infection occurs) with immunoglobulin-replacement therapy improves survival  in patients with myeloma treated with BCMA bispecific antibodies. 

There will be several presentations dedicated to CAR T-cell therapies for the treatment of myeloma, including: 

• CB-011: early results from the phase I CAMMOUFLAGE clinical trial show the safety and preliminary efficacy of the allogeneic anti-BCMA CAR T-cell therapy CB-011 in patients with relapsed or refractory myeloma. 
• Arlocabtagene autoleucel: an updated phase I clinical trial results show promising safety and efficacy of the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in patients with relapsed or refractory myeloma who received 1 to 3 prior lines of treatment. 
• BMS-986453: preclinical and early clinical development data showing the potential of the dual-targeting BCMA andGPRC5D CAR T-cell therapy BMS-986453 in patients with relapsed or refractory myeloma.

The treatment of newly diagnosed myeloma patients will also be addressed in several presentations, including:

• Daratumumab + VRd: final analysis from the phase III CEPHEUS clinical trial confirms previously reported efficacy and safety results demonstrating the benefits of adding daratumumab to the bortezomib, lenalidomide, and dexamethasone treatment combination in transplant-ineligible patients with newly diagnosed myeloma.
• Iberdomide + DVd: phase I/II results from the IDEAL clinical trial show the safety and efficacy of an iberdomide-based quadruplet regimen with daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed myeloma.

Smouldering myeloma treatment will also be covered, with a few presentations, including:

• Elranatamab: first results from the phase II EMN34/ERASMM clinical trial show the safety and efficacy of elranatamab as a promising early intervention strategy in patients with high-risk smouldering myeloma. 

Several presentations will focus on AL amyloidosis treatment, including:

• Anselamimab: results from the phase III CARES clinical trial show a survival benefit of adding the amyloid depleter anselamimab (also known as CAEL-101) to standard treatments in patients with newly diagnosed stage IIIa and IIIb AL amyloidosis.
• Linvoseltamab: early efficacy and safety results from the phase I/II LINKER AL2 clinical trial show promising results for the BCMA bispecific antibody linvoseltamab in patients with relapsed or refractory AL amyloidosis.
• Etentamig: safety and efficacy results from the phase I clinical trial confirm previously reported promising results for the BCMA bispecific antibody etentamig in patients with relapsed or refractory AL amyloidosis.

MPE at EHA 2026

MPE will attend EHA 2026 to gather the most important updates on myeloma and AL amyloidosis and other key advocacy topics such as access to treatment and quality of life for patients. In particular, MPE will participate in the following sessions:

• MPE board member, Snežana Doder, will share patients’ perspectives on treatment access during the session “Inequalities in drug access in lymphoid malignancies (multiple myeloma)” co-chaired by MPE President, Barbara Leonardi on Sunday, 14 June. 

• MPE Head of Patient Research, Eilidh Duncan, will speak about shared decision-making and patients’ perspectives on treatment administration routes during the satellite symposium  “Individualisation Requires Communication: Working With Our Patients With Newly-Diagnosed Multiple Myeloma (NDMM) to Optimise Treatment Outcomes”, which will take place on Saturday, 13 June. 

• MPE Head of Medical Education and Scientific Engagement, Solène Clavreul,  along with  Scientific and Data Strategy Lead at TriNetX,  Zuzana  Dostálová, will present the results of MPE and  TriNetX’s collaborative research on real-world eligibility and treatment decision factors, alternative treatments and outcomes of myeloma patients considered for CAR T-cell therapy in Germany in the poster session on Friday, 12 June.  

• MPE Head of Patient Research, Eilidh Duncan, will present the results of MPE’s research on real-world experiences of family carers supporting people with myeloma in the poster session on Friday, 12 June.  

With so much data being presented, EHA 2026 promises to be an exciting meeting for the myeloma and AL amyloidosis community. MPE looks forward to sharing insights and analysis throughout and in the weeks after the event, including our EHA highlights webinar.So, be sure to follow us on all our channels for full coverage and register for our upcoming webinar!